Drug
B007
B007 is a pharmaceutical drug with 4 clinical trials. Currently 4 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(100%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_2
3
75%
Phase Distribution
1
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 23 (75.0%)
Trials by Status
recruiting4100%
Recent Activity
4 active trials
Showing 4 of 4
recruitingphase_2
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06470191
recruitingphase_2
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357
recruitingphase_2
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597
recruitingphase_1
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT05668403
Clinical Trials (4)
Showing 4 of 4 trials
NCT06470191Phase 2
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
NCT06454357Phase 2
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06447597Phase 2
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT05668403Phase 1
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4